Your local Pfizer representative/Healthcare Partnership Manager can provide you with guidance on how to initiate NGENLA for your patients. Access guidance on how to contact us here.

Newly diagnosed paediatric Growth Hormone Deficiency (pGHD) patients

NGENLA is indicated for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of Growth Hormone (GH). The recommended dose is 0.66 mg/kg body weight administered once weekly by subcutaneous injection.^{1​​​​}

Current pGHD patients who are currently on daily GH

Consider NGENLA for your pGHD patients aged 3 years or older who are currently on daily GH treatment, and may benefit from once-weekly treatment. These may include:

• Patients who prefer a less frequent injection schedule
• Patients currently on a daily GH, who are transitioning to injecting themselves.

Switch to Ngenla in 3 easy steps:¹

1. Prescribe NGENLA at a dose of 0.66mg/kg/week and ensure the relevant device training has taken place 
2. Start patients on Ngenla the day after Daily Growth Hormone is discontinued 
3. Administer Ngenla weekly thereafter 

A higher proportion of patients/caregivers indicated a greater intention to comply with the treatment schedule for once-weekly somatrogon compared with once-daily Somatropin²NGENLA delivered a favoured treatment experience for patients and caregivers in a phase 3 crossover study versus daily Genotropin (somatropin) in pGHD, based on lower treatment burden as shown by less life interference, using a range of parameters.

Life interference parameter overall mean scores where patients and caregivers favoured once weekly NGENLA (95% CI) after 12 weeks vs. once daily Genotropin included: willingness to continue treatment, impact on daily activities, caregiver & family life interference and convenience & ease of the injection schedule.

The most commonly reported adverse reactions after treatment with NGENLA are injection site reactions (ISRs) (25.1%), headache (10.7%) and pyrexia (10.2%).¹

For further information on safety & efficacy data click here.

Study Design

Patients and caregivers (N=87) reported improved (lower) Life Interference total score after 12 weeks of once-weekly NGENLA treatment compared to once-daily GH.^1,2 Phase 3, randomised, open-label, 2-period, crossover, multicentre study assessing patient perception of treatment burden with the use of NGENLA once weekly versus Genotropin once daily in children 3 to <18 years of age with GH deficiency.^1,2
Data are based on patient/caregiver recall following each 12-week treatment period and at the end of the study. Caregivers completed the assessment for children under 8 years of age.²
† Based on Patient Global Impression Severity-Impact on Daily Activities.²